PCV43 COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT
May 1, 2011, 00:00
10.1016/j.jval.2011.02.230
https://www.valueinhealthjournal.com/article/S1098-3015(11)00369-X/fulltext
Title :
PCV43 COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)00369-X&doi=10.1016/j.jval.2011.02.230
First page :
A40
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
782